Literature DB >> 31320555

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.

Esperanza M Algarín1, Andrea Díaz-Tejedor1, Pedro Mogollón1, Susana Hernández-García1, Luis A Corchete1, Laura San-Segundo1, Montserrat Martín-Sánchez1, Lorena González-Méndez1, Marie Schoumacher2, Sebastien Banquet2, Laurence Kraus-Berthier2, Ioana Kloos2, Alix Derreal2, Ensar Halilovic3, Heiko Maacke4, Norma C Gutiérrez1, María-Victoria Mateos1, Teresa Paíno1, Mercedes Garayoa1, Enrique M Ocio5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31320555      PMCID： PMC7049360          DOI： 10.3324/haematol.2018.212308

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

Authors:  Christelle Dousset; Sophie Maïga; Patricia Gomez-Bougie; Joy Le Coq; Cyrille Touzeau; Philippe Moreau; Steven Le Gouill; David Chiron; Catherine Pellat-Deceunynck; Agnès Moreau-Aubry; Martine Amiot
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

2.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Authors:  Delphine Merino; James R Whittle; François Vaillant; Antonin Serrano; Jia-Nan Gong; Goknur Giner; Ana Leticia Maragno; Maïa Chanrion; Emilie Schneider; Bhupinder Pal; Xiang Li; Grant Dewson; Julius Gräsel; Kevin Liu; Najoua Lalaoui; David Segal; Marco J Herold; David C S Huang; Gordon K Smyth; Olivier Geneste; Guillaume Lessene; Jane E Visvader; Geoffrey J Lindeman
Journal:  Sci Transl Med       Date:  2017-08-02       Impact factor: 17.956

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Authors:  András Kotschy; Zoltán Szlavik; James Murray; James Davidson; Ana Leticia Maragno; Gaëtane Le Toumelin-Braizat; Maïa Chanrion; Gemma L Kelly; Jia-Nan Gong; Donia M Moujalled; Alain Bruno; Márton Csekei; Attila Paczal; Zoltán B Szabo; Szabolcs Sipos; Gábor Radics; Agnes Proszenyak; Balázs Balint; Levente Ondi; Gábor Blasko; Alan Robertson; Allan Surgenor; Pawel Dokurno; Ijen Chen; Natalia Matassova; Julia Smith; Christopher Pedder; Christopher Graham; Aurélie Studeny; Gaëlle Lysiak-Auvity; Anne-Marie Girard; Fabienne Gravé; David Segal; Chris D Riffkin; Giovanna Pomilio; Laura C A Galbraith; Brandon J Aubrey; Margs S Brennan; Marco J Herold; Catherine Chang; Ghislaine Guasconi; Nicolas Cauquil; Fabien Melchiore; Nolwen Guigal-Stephan; Brian Lockhart; Frédéric Colland; John A Hickman; Andrew W Roberts; David C S Huang; Andrew H Wei; Andreas Strasser; Guillaume Lessene; Olivier Geneste
Journal:  Nature       Date:  2016-10-19       Impact factor: 49.962

5.  Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders.

Authors:  T E Witzig; M Timm; D Larson; T Therneau; P R Greipp
Journal:  Br J Haematol       Date:  1999-01       Impact factor: 6.998

6.  Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

Authors:  Jia-Nan Gong; Tiffany Khong; David Segal; Yuan Yao; Chris D Riffkin; Jean-Marc Garnier; Seong Lin Khaw; Guillaume Lessene; Andrew Spencer; Marco J Herold; Andrew W Roberts; David C S Huang
Journal:  Blood       Date:  2016-07-27       Impact factor: 22.113

7.  Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Authors:  Elizabeth A Punnoose; Joel D Leverson; Franklin Peale; Erwin R Boghaert; Lisa D Belmont; Nguyen Tan; Amy Young; Michael Mitten; Ellen Ingalla; Walter C Darbonne; Anatol Oleksijew; Paul Tapang; Peng Yue; Jason Oeh; Leslie Lee; Sophie Maiga; Wayne J Fairbrother; Martine Amiot; Andrew J Souers; Deepak Sampath
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

8.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

9.  BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.

Authors:  C Touzeau; J Ryan; J Guerriero; P Moreau; T N Chonghaile; S Le Gouill; P Richardson; K Anderson; M Amiot; A Letai
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

10.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Authors:  C Touzeau; C Dousset; S Le Gouill; D Sampath; J D Leverson; A J Souers; S Maïga; M C Béné; P Moreau; C Pellat-Deceunynck; M Amiot
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528
View more
  17 in total

1.  Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.

Authors:  Anne Slomp; Laura M Moesbergen; Jia-Nan Gong; Marta Cuenca; Peter A von dem Borne; Pieter Sonneveld; David C S Huang; Monique C Minnema; Victor Peperzak
Journal:  Blood Adv       Date:  2019-12-23

2.  Identification of bicyclic compounds that act as dual inhibitors of Bcl-2 and Mcl-1.

Authors:  Abhay Uthale; Aarti Anantram; Prasad Sulkshane; Mariam Degani; Tanuja Teni
Journal:  Mol Divers       Date:  2022-07-31       Impact factor: 3.364

Review 3.  Enhancing venetoclax activity in hematological malignancies.

Authors:  Toshihisa Satta; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2020-07-16       Impact factor: 6.206

4.  The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA.

Authors:  Hans-Georg Kopp; Frank Essmann; Sandra Weller; Astrid Toennießen; Benjamin Schaefer; Tobias Beigl; Alina Muenchow; Kathrin Böpple; Ute Hofmann; Bernhard F Gillissen; Walter E Aulitzky
Journal:  Cell Death Discov       Date:  2022-04-20

5.  Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.

Authors:  Sherry Bhalla; David T Melnekoff; Adolfo Aleman; Violetta Leshchenko; Paula Restrepo; Jonathan Keats; Kenan Onel; Jeffrey R Sawyer; Deepu Madduri; Joshua Richter; Shambavi Richard; Ajai Chari; Hearn Jay Cho; Joel T Dudley; Sundar Jagannath; Alessandro Laganà; Samir Parekh
Journal:  Sci Adv       Date:  2021-11-17       Impact factor: 14.136

Review 6.  BH3-mimetics: recent developments in cancer therapy.

Authors:  Paul A Townsend; Maria V Kozhevnikova; Olivier N F Cexus; Andrey A Zamyatnin; Surinder M Soond
Journal:  J Exp Clin Cancer Res       Date:  2021-11-09

7.  Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.

Authors:  Carolane Seiller; Sophie Maiga; Cyrille Touzeau; Céline Bellanger; Charlotte Kervoëlen; Géraldine Descamps; Laurent Maillet; Philippe Moreau; Catherine Pellat-Deceunynck; Patricia Gomez-Bougie; Martine Amiot
Journal:  Cell Death Dis       Date:  2020-05-05       Impact factor: 8.469

Review 8.  Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.

Authors:  Maxime Jullien; Patricia Gomez-Bougie; David Chiron; Cyrille Touzeau
Journal:  Cells       Date:  2020-03-14       Impact factor: 6.600

9.  Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.

Authors:  Esperanza M Algarín; Dalia Quwaider; Francisco J Campos-Laborie; Andrea Díaz-Tejedor; Pedro Mogollón; Elena Vuelta; Montserrat Martín-Sánchez; Laura San-Segundo; Lorena González-Méndez; Norma C Gutiérrez; Ramón García-Sanz; Teresa Paíno; Javier De Las Rivas; Enrique M Ocio; Mercedes Garayoa
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

Review 10.  Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.

Authors:  Omar Al-Odat; Max von Suskil; Robert Chitren; Weam Elbezanti; Sandeep Srivastava; Tulin Budak-Alpddogan; Subash Jonnalagadda; Bharat Aggarwal; Manoj Pandey
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.